pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Drug Delivery Technologies & Formulation Conference in Switzerland

pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Drug Delivery Technologies & Formulation Conference in Switzerland

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });

IN US:Martin E. Janis & Company, Inc.Beverly Jedynak, President312-943-1123orIn Australia:pSivida Corp.Brian Leedman, Vice President, Investor Relations+61 (0) 41 228 1780

pSivida Corp. (NASDAQ:) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that Dr. Paul Ashton, President and CEO, has been invited to participate as a distinguished speaker at the Drug Delivery Technologies & Formulation Conference taking place on September 5-6 in Zurich Switzerland. Dr. Ashton’s topic is: “Eye Opening: Sustained Delivery and Nanotechnology in Ophthalmology.”

Dr. Ashton’s talk will focus on strategies and opportunities in delivery of ophthalmic drugs, many of which must be injected directly into the eye frequently, often monthly, for the duration of a patient’s life. His talk will focus on methods for enhanced topical delivery, long term intraocular delivery and novel surgical approaches. pSivida most recently announced a fully funded technology evaluation agreement with a leading global biopharmaceutical company to evaluate pSivida’s Tethadur™ protein/antibody delivery technology in the field of ophthalmology. Tethadur™ is an application of pSivida’s BioSilicon™ technology platform designed to provide sustained delivery of large biologic molecules, including proteins, antibodies and peptides.

The conference is designed to provide education, communication and networking opportunities for both scientific and business leaders engaged in drug delivery and formulation and includes speakers from academia, biotech and industry to discuss current and new strategies to succeed in this evolving area.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME), licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal and the U.K. and is awaiting authorization in Italy and Spain. The United States Food and Drug Administration (FDA) has cleared pSivida’s Investigational New Drug application (IND) to treat posterior uveitis with the same micro-insert. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular hypertension. pSivida’s two FDA-approved products, Retisert® and Vitrasert®, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_2__mobile'); }); });